Sclerosis, Systemic clinical trials at UC Health
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.